Capricor Therapeutics Inc
Research Capricor Therapeutics Inc (CAPR) on Bullrun: market cap USD 481.72M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCAPR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 481.72M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 114.59M
- Free cash flow-USD 40.00M
Valuation Snapshot
latest market cap is USD 481.72M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 105.04M | -USD 72.72M | n/a | -2.26 | USD 287.85M | USD 14.52M | USD 305.79M |
| FY2024 | USD 22.27M | -USD 40.47M | -USD 41.16M | n/a | -1.15 | USD 11.29M | USD 1.45M | USD 145.46M |
| FY2023 | USD 25.18M | -USD 22.29M | -USD 26.91M | n/a | -0.83 | USD 14.69M | USD 2.24M | USD 22.60M |
| FY2022 | USD 2.55M | -USD 29.02M | USD 2.92M | n/a | -1.18 | USD 9.60M | USD 2.74M | USD 11.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 481.72M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.66B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 629.04M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 150.58M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 97.43M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 70.86M | n/a | n/a | n/a |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Capricor Therapeutics Inc's market cap?
Capricor Therapeutics Inc's market capitalization is USD 481.72M.
What does Capricor Therapeutics Inc do?
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.